Skip to content

Effect of uric acid lowering therapy on joint bone erosion in patients with gout and asymptomatic hyperuricemia

Association of uric acid lowering therapy with bone erosion in gout and asymptomatic hyperuricemia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061649
Enrollment
Unknown
Registered
2022-06-30
Start date
2022-06-16
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

Sponsors

Shanghai Tenth People's Hospital, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 65 Years

Inclusion criteria

Inclusion criteria: Gout group: 1. Patients diagnosed with gout according to the 2015 ACR/EULAR gout classification criteria; 2. Aged > 18 years; 3. In accordance with the American College of Rheumatology guidelines for Gout Treatment 2020, Treatment indications of ULT: Start ULT for patients with any of the following conditions: >= 1 subcutaneous tophi; Radiographic injury due to gout (in any form); The frequency of gout was defined as >= 2 times/year. Hyperuricemia group: 1. Blood uric acid level exceeded 420 µmol/L twice on different days. 2. Asymptomatic HUA patients can start uric-lowering drug therapy when the following conditions occur: blood uric acid level >= 540 µmol/L or blood uric acid level >= 480 µmol/L and one of the following complications: hypertension, abnormal lipid metabolism, diabetes, obesity, stroke, coronary heart disease, cardiac insufficiency, uric acid nephrolithiasis, renal impairment (CKD stage 2 and above).

Exclusion criteria

Exclusion criteria: 1. Patients who did not adhere to ULT as required; 2. Patients with other bone and joint diseases, including osteoarthritis, rheumatoid arthritis or psoriatic arthritis, etc.

Design outcomes

Primary

MeasureTime frame
Blood uric acid value;Double contour sign;tophus;bony erosion;

Secondary

MeasureTime frame
Synovial membrane thickness;Synovial blood flow;

Countries

China

Contacts

Public ContactHui Zhao

Shanghai Tenth People's Hospital, Tongji University

zhaohui2022@163.com+86 15998310950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026